Next-generation total-body PET scanner can produce diagnostic-quality images in as little as 1 minute - Medical Xpress

The scanner's fastest images were rated more highly on average than those from a standard PET/CT scanner.

A roar of laughter erupts from a crowd inside a large conference room at the De Vere Cranage Estate hotel. The joke? The idea that visiting the doctor could help treat a serious illness. On stage the controversial Australian proponent of natural remedies Barbara O’Neill is taking part in a question-and-answer session during a five-day wellness conference, where science mixes uncomfortably with Bible verse and potentially deadly pseudo-scientific practices. She is advising people attending at the event in Cheshire on a variety of medical ailments, and dismisses the use of antibiotics, vaccines or scientifically proven cancer treatment. Tickets for the residential retreat can cost up to £1,300. An undercover reporter for the Guardian attended for one day, observing four sessions covering topics including the immune system and one titled Barbara Under Attack. The audience’s rapturous laughter is prompted by a woman asking O’Neill if there is anything that could help her lupus, which she says has not responded well to the doctor’s treatments. “Yes, keep away from the doctor,” quips O’Neill.

Patients receiving oral anticoagulation (OAC) for atrial fibrillation frequently have concomitant coronary artery disease (CAD), raising questions about the duration of additional antiplatelet therapy. Triple antithrombotic therapy combines OAC with aspirin and a P2Y₁₂ inhibitor, usually clopidogrel, whereas dual antithrombotic therapy combines OAC with a single antiplatelet agent. Early aspirin withdrawal from triple therapy and subsequent withdrawal of the remaining antiplatelet are separate decisions requiring assessment of the coronary timeline and current treatment indications. This narrative editorial examines randomized evidence and proposes a structured medication review framework. The evidence generally supports OAC monotherapy in appropriately selected patients with stable CAD, with reduced bleeding and favourable net clinical outcomes compared with combined treatment. However, aspirin-specific findings require distinction from comparisons involving clopidogrel or mixed antiplatelet regimens. Overall trial results do not establish identical benefits or harms across patients with previous myocardial infarction, multivessel disease, or complex coronary intervention. Differe